Literature DB >> 17657591

Mammalian mismatches in nucleotide metabolism: implications for xenotransplantation.

Zain Khalpey1, Ada H Y Yuen, Marialuisa Lavitrano, Christopher G A McGregor, Kameljit K Kalsi, Magdi H Yacoub, Ryszard T Smolenski.   

Abstract

Acute humoral rejection (AHR) limits the clinical application of animal organs for xenotransplantation. Mammalian disparities in nucleotide metabolism may contribute significantly to the microvascular component in AHR; these, however remain ill-defined. We evaluated the extent of species-specific differences in nucleotide metabolism. HPLC analysis was performed on venous blood samples (nucleotide metabolites) and heart biopsies (purine enzymes) from wild type mice, rats, pigs, baboons, and human donors.Ecto-5'-nucleotidase (E5'N) activities were 4-fold lower in pigs and baboon hearts compared to human and mice hearts while rat activity was highest. Similar differences between pigs and humans were also observed with kidneys and endothelial cells. More than 10-fold differences were observed with other purine enzymes. AMP deaminase (AMPD) activity was exceptionally high in mice but very low in pig and baboon hearts. Adenosine deaminase (ADA) activity was highest in baboons. Adenosine kinase (AK) activity was more consistent across different species. Pig blood had the highest levels of hypoxanthine, inosine and adenine. Human blood uric acid concentration was almost 100 times higher than in other species studied. We conclude that species-specific differences in nucleotide metabolism may affect compatibility of pig organs within a human metabolic environment. Furthermore, nucleotide metabolic mismatches may affect clinical relevance of animal organ transplant models. Supplementation of deficient precursors or application of inhibitors of nucleotide metabolism (e.g., allopurinol) or transgenic upregulation of E5'N may overcome some of these differences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657591     DOI: 10.1007/s11010-007-9491-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  46 in total

1.  Thromboregulation by endothelial cells: significance for occlusive vascular diseases.

Authors:  S C Robson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-07       Impact factor: 8.311

2.  5'-Adenosine monophosphate and adenosine metabolism, and adenosine responses in mouse, rat and guinea pig heart.

Authors:  J P Headrick; J Peart; B Hack; B Garnham; G P Matherne
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2001-11       Impact factor: 2.320

3.  Transplant accommodation.

Authors:  Alexandros Delikouras; Anthony Dorling
Journal:  Am J Transplant       Date:  2003-08       Impact factor: 8.086

4.  Protection from reperfusion injury after cardiac transplantation by inhibition of adenosine metabolism and nucleotide precursor supply.

Authors:  R T Smolenski; O Raisky; E M Slominska; H Abunasra; K K Kalsi; J Jayakumar; K Suzuki; M H Yacoub
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

Review 5.  Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.

Authors:  Simon C Robson; Yan Wu; Xiaofeng Sun; Christoph Knosalla; Karen Dwyer; Keiichi Enjyoji
Journal:  Semin Thromb Hemost       Date:  2005-04       Impact factor: 4.180

6.  Kinetics of adenylate metabolism in human and rat myocardium.

Authors:  M Tavenier; A C Skladanowski; R A De Abreu; J W de Jong
Journal:  Biochim Biophys Acta       Date:  1995-06-09

7.  Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients.

Authors:  David Goldsmith; Elizabeth A Carrey; Stephen Edbury; Ryszard T Smolenski; Piotr Jagodzinski; H Anne Simmonds
Journal:  Clin Sci (Lond)       Date:  2004-07       Impact factor: 6.124

8.  Impairment of tubuloglomerular feedback regulation of GFR in ecto-5'-nucleotidase/CD73-deficient mice.

Authors:  Hayo Castrop; Yuning Huang; Seiji Hashimoto; Diane Mizel; Pernille Hansen; Franziska Theilig; Sebastian Bachmann; Chuxia Deng; Josie Briggs; Jurgen Schnermann
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

9.  Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors.

Authors:  B N Cronstein; R I Levin; M Philips; R Hirschhorn; S B Abramson; G Weissmann
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

Review 10.  Targeting G protein-coupled A2a adenosine receptors to engineer inflammation in vivo.

Authors:  Gregorio Gomez; Michail V Sitkovsky
Journal:  Int J Biochem Cell Biol       Date:  2003-04       Impact factor: 5.085

View more
  5 in total

Review 1.  T-cell-mediated immunological barriers to xenotransplantation.

Authors:  Joseph Scalea; Isabel Hanecamp; Simon C Robson; Kazuhiko Yamada
Journal:  Xenotransplantation       Date:  2012 Jan-Feb       Impact factor: 3.907

Review 2.  Current progress in xenogeneic tolerance.

Authors:  Kazuhiko Yamada; Joseph Scalea
Journal:  Curr Opin Organ Transplant       Date:  2012-04       Impact factor: 2.640

Review 3.  Current status of xenotransplantation and prospects for clinical application.

Authors:  Richard N Pierson; Anthony Dorling; David Ayares; Michael A Rees; Jörg D Seebach; Jay A Fishman; Bernhard J Hering; David K C Cooper
Journal:  Xenotransplantation       Date:  2009 Sep-Oct       Impact factor: 3.907

4.  Improved metabolism and redox state with a novel preservation solution: implications for donor lungs after cardiac death (DCD).

Authors:  David A Schipper; Anthony V Louis; Destiny S Dicken; Kitsie Johnson; Ryszard T Smolenski; Stephen M Black; Ray Runyan; John Konhilas; Joe G N Garcia; Zain Khalpey
Journal:  Pulm Circ       Date:  2017-05-24       Impact factor: 3.017

5.  Nucleotide metabolic mismatches in mammalian hearts: implications for transplantation.

Authors:  Z Khalpey; M H Yacoub; R T Smolenski
Journal:  Ann R Coll Surg Engl       Date:  2013-01       Impact factor: 1.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.